{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:21:19Z","timestamp":1783621279208,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjcard.2026.04.052","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:41:33Z","timestamp":1778578893000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanisms, Magnitude, and Consequence of Acute Estimated Glomerular Filtration Rate Change With Guideline-Directed Medical Therapy Initiation in Heart Failure"],"prefix":"10.1016","volume":"272","author":[{"given":"Tariq","family":"Shafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane A.","family":"Bobart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0001","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"10.1016\/j.amjcard.2026.04.052_bib0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41581-019-0191-y","article-title":"Measured and estimated glomerular filtration rate: current status and future directions","volume":"16","author":"Levey","year":"2020","journal-title":"Nat Rev Nephrol."},{"issue":"8","key":"10.1016\/j.amjcard.2026.04.052_bib0003","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.7326\/M22-0610","article-title":"Quantifying individual-level inaccuracy in glomerular filtration rate estimation","volume":"175","author":"Shafi","year":"2022","journal-title":"Ann Intern Med."},{"issue":"7","key":"10.1016\/j.amjcard.2026.04.052_bib0004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.amjcard.2026.04.052_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: definitions, mechanisms and clinical implications","volume":"8","author":"Helal","year":"2012","journal-title":"Nat Rev Nephrol."},{"issue":"10","key":"10.1016\/j.amjcard.2026.04.052_bib0006","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2337\/dc11-2189","article-title":"Glomerular hyperfiltration and renal disease progression in type 2 diabetes","volume":"35","author":"Ruggenenti","year":"2012","journal-title":"Diabetes Care."},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0007","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1001\/jamacardio.2023.4553","article-title":"Optimization of evidence-based heart failure medications after an acute heart failure admission: a secondary analysis of the STRONG-HF randomized clinical trial","volume":"9","author":"Cotter","year":"2024","journal-title":"JAMA Cardiol."},{"issue":"15","key":"10.1016\/j.amjcard.2026.04.052_bib0008","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"12","key":"10.1016\/j.amjcard.2026.04.052_bib0009","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: national guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart."},{"issue":"5","key":"10.1016\/j.amjcard.2026.04.052_bib0010","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med."},{"issue":"4","key":"10.1016\/j.amjcard.2026.04.052_bib0011","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension."},{"issue":"5","key":"10.1016\/j.amjcard.2026.04.052_bib0012","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360."},{"issue":"4","key":"10.1016\/j.amjcard.2026.04.052_bib0013","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur J Heart Fail."},{"issue":"8","key":"10.1016\/j.amjcard.2026.04.052_bib0014","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"O\u2019Hara","year":"2024","journal-title":"Nat Rev Nephrol."},{"issue":"Suppl 2","key":"10.1016\/j.amjcard.2026.04.052_bib0015","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.amjcard.2026.04.052_bib0016","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"10.1016\/j.amjcard.2026.04.052_bib0017","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res."},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0018","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension."},{"issue":"5","key":"10.1016\/j.amjcard.2026.04.052_bib0019","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.amjcard.2026.04.052_bib0020","series-title":"Comprehensive physiology.","first-page":"965","article-title":"The multifaceted mineralocorticoid receptor","author":"Gomez-Sanchez","year":"2014"},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2011.06.014","article-title":"Mineralocorticoid receptors in vascular function and disease","volume":"350","author":"McCurley","year":"2012","journal-title":"Mol Cell Endocrinol."},{"issue":"11","key":"10.1016\/j.amjcard.2026.04.052_bib0022","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs."},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0023","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J."},{"issue":"19","key":"10.1016\/j.amjcard.2026.04.052_bib0024","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA."},{"issue":"3","key":"10.1016\/j.amjcard.2026.04.052_bib0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int."},{"issue":"24","key":"10.1016\/j.amjcard.2026.04.052_bib0026","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.amjcard.2026.04.052_bib0027","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.amjcard.2026.04.052_bib0028","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"10.1016\/j.amjcard.2026.04.052_bib0029","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.amjcard.2026.04.052_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"22","key":"10.1016\/j.amjcard.2026.04.052_bib0031","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.amjcard.2026.04.052_bib0032","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int."},{"issue":"21","key":"10.1016\/j.amjcard.2026.04.052_bib0033","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol."},{"issue":"9","key":"10.1016\/j.amjcard.2026.04.052_bib0034","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail."},{"issue":"1","key":"10.1016\/j.amjcard.2026.04.052_bib0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","article-title":"Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis","volume":"108","author":"Navaneethan","year":"2025","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0036","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2024.11.020","article-title":"Initial decline in glomerular filtration rate with finerenone in HFmrEF\/HFpEF","volume":"85","author":"Matsumoto","year":"2025","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0037","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0038","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ndt\/gfp510","article-title":"Development and validation of GFR-estimating equations using diabetes, transplant and weight","volume":"25","author":"Stevens","year":"2010","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"10.1016\/j.amjcard.2026.04.052_bib0039","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MNH.0000000000000854","article-title":"Traditions and innovations in assessment of glomerular filtration rate using creatinine to cystatin C","volume":"32","author":"Tio","year":"2023","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"14","key":"10.1016\/j.amjcard.2026.04.052_bib0040","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"JACC."},{"issue":"2","key":"10.1016\/j.amjcard.2026.04.052_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24244","article-title":"The effect of kidney function on guideline-directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction","volume":"47","author":"B\u00e1nfi-Bacs\u00e1rdi","year":"2024","journal-title":"Clin Cardiol."},{"issue":"12","key":"10.1016\/j.amjcard.2026.04.052_bib0042","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/ejhf.3074","article-title":"Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure","volume":"25","author":"Ter Maaten","year":"2023","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.amjcard.2026.04.052_bib0043","series-title":"Simultaneous versus sequential initiation of HFrEF therapies","author":"Brownell","year":"2022"},{"key":"10.1016\/j.amjcard.2026.04.052_bib0044","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2021.18","article-title":"The gap to fill: rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction","volume":"7","author":"Brownell","year":"2021","journal-title":"Card Fail Rev."},{"issue":"1","key":"10.1016\/j.amjcard.2026.04.052_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2020.08.017","article-title":"Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients","volume":"9","author":"Srivastava","year":"2021","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.amjcard.2026.04.052_bib0046","first-page":"1","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"392","author":"Agarwal","year":"2025","journal-title":"N Engl J Med."},{"issue":"687","key":"10.1016\/j.amjcard.2026.04.052_bib0047","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.3399\/bjgp19X705497","article-title":"Using chronic kidney disease trigger tools for safety and learning: a qualitative evaluation in East London primary care","volume":"69","author":"Thomas","year":"2019","journal-title":"Br J Gen Pract."}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926003097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:01:33Z","timestamp":1783620093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926003097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0002914926003097"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.04.052","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms, Magnitude, and Consequence of Acute Estimated Glomerular Filtration Rate Change With Guideline-Directed Medical Therapy Initiation in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.04.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}